Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments

REFERENCES

1. 1.↵
   1. Gladman DD,
   2. Antoni C,
   3. Mease P,
   4. Clegg DO,
   5. Nash P

   . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14–ii7.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Sokoll KB,
   2. Helliwell PS

   . Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842–6.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Coates LC,
   2. Fransen J,
   3. Helliwell PS

   . Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Helliwell PS,
   2. FitzGerald O,
   3. Fransen J,
   4. Gladman DD,
   5. Kreuger GG,
   6. Callis-Duffin K,
   7. et al.

   The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Coates LC,
   2. Moverley AR,
   3. McParland L,
   4. Brown S,
   5. Collier H,
   6. Law J,
   7. et al.

   Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Arthritis Rheum 2013;65 Suppl a10:814.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Coates LC,
   2. Helliwell PS

   . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–9.

   OpenUrlCrossRef
7. 7.↵
   1. Mumtaz A,
   2. Gallagher P,
   3. Kirby B,
   4. Waxman R,
   5. Coates LC,
   6. Veale JD,
   7. et al.

   Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272–7.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Helliwell PS,
   2. FitzGerald O,
   3. Fransen J

   . Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014;41:1212–7.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Coates LC,
   2. Moverley AR,
   3. McParland L,
   4. Brown S,
   5. Navarro-Coy N,
   6. O’Dwyer J,
   7. et al.

   Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015 Sept 30 (E-pub ahead of print).
10. 10.↵
    1. Cantini F,
    2. Niccoli L,
    3. Nannini C,
    4. Cassarà E,
    5. Pasquetti P,
    6. Olivieri I,
    7. et al.

    Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 2008;47:872–6.

    OpenUrlAbstract/FREE Full Text